The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
30
No.
40
October 22, 2004
- As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.
- Also in this 8-page issue: M.D. Anderson Cancer Center wins ninth SPORE grant, this time for melanoma research.
- Fox Chase Cancer Center plans $1 billion expansion that would double its size.
- Human Genome Project publishes its final product.
TCL
Vol.
30
No.
41
October 29, 2004
- Special Report on the American Legacy Foundation: As Legacy seeks new funding, critics fear symbiosis with Big Tobacco. Legacy, NCI, C-Change relationship could open door to industry influence, lawyer says.
- Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”
- NCI-supported meeting included tobacco industry representatives in dialogue on ethics.
- Also David Schwartz of Duke University to head NIEHS.
- NCI funds nine centers for $14.9 million integrative biology program.
- NIH awards 1,400 student loan repayment contracts.
- Funding opportunities listed.
CCL
Vol.
27
No.
10
October 29, 2004
- Sister Study To Examine Risk Factors For Breast Cancer In 50,000 Women
- Some Children With Hodgkin’s Disease Can Reduce Or Skip Radiation, Study Finds
- Breast Implants Don’t Cause Tissue Disorders, NCI Finds
- Unscreened Women At High Risk of Breast Cancer
- Efaproxyn Improved Survival Of Patients With Brain Mets
- Brachytherapy Better Than Surgery For Prostate Cancer
- Ohio Center Helps Women Stop Smoking, Reduce Cervical Cancer Risk
- Smoking Cessation Training Follows Doctors Into Practice
- Degarelix Active In Phase II Trial In Prostate Cancer
- Study Opens For Women At Risk of Ovarian Cancer
- Centers Recruting Patients With Mantle Cell Lymphoma
- NCI-Approved Clinical Trials
TCL
Vol.
30
No.
42
November 05, 2004
- Medicare increases payments for oncology infusion and begins a one-year demonstration project that pays oncologists to assess the side effects of chemotherapy.
- CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.
- Also Unclear whether HHS Secretary Tommy Thompson will depart as previously planned.
- California approves $3 billion program for stem-cell research.
- Oklahoma’s new cigarette tax will provide $7 million a year to the University of Oklahoma Cancer Center.
- National Cancer Policy Board will end in 2005, NCI to support a cancer forum at IOM.
- Funding opportunities listed.
- October issue of Business & Regulatory Report included.
TCL
Vol.
30
No.
43
November 12, 2004
- Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
- Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
- NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
- St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
- Funding opportunities listed.
TCL
Vol.
30
No.
44
November 19, 2004
- NCI advisors approve recompetition of $62 million phase II contracts program.
- Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.
- Advisors approve set-aside for alternative medicine “best case series.”
- HHS bans tobacco from its campuses, opens national quitline, 1-800-QUITNOW.
- Two founding cancer center directors step down: Harold Moses at Vanderbilt-Ingram and Charles Coltman at CTRC.
- Funding opportunities listed.
- November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.
CCL
Vol.
27
No.
11
November 26, 2004
- Bevacizumab Prolongs Survival In Patients With Advanced Colorectal Cancer
- Anidulafungin Safe And Well-Tolerated In Pediatric Patients With Neutropenia
- Dexamethasone Improved Survival Of Leukemia
- Intense Therapies Better Than Lower Dose For AML
- No Link Between Pneumonitis, Taxanes, And Radiation
- Artificial Neural Networks Predict Clinical Outcomes
- ASCO And ESMO Publish Training Recommendations
- NCI-Approved Clinical Trials
TCL
Vol.
30
No.
45
December 03, 2004
- NCI’s projected 2.7 percent budget increase for FY 2005 will be insufficient to cover the Institute’s commitments, Director Andrew von Eschenbach said. Planning for new programs will continue nonetheless. NCI is an elephant that will have to learn to dance, he said. NCI director’s new favorite metaphor has a long history, from “The Jungle Book” to a business memoir about IBM.
- Also in this 8-page issue: House Committee on Energy and Commerce is investigating the collapse of the Institute for Cancer Prevention, which owes $5.7 million to NCI.
- HHS Secretary Tommy Thompson announced his resignation.
- American Cancer Society elected new officers.
- Funding opportunties listed.